Factors associated with emergency department (ED) attendance during last month of life
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers from King's College London Cicely Saunders Institute in London, United Kingdom, have identified demographic and environmental factors associated with an increased risk of emergency department visits by patients with cancer during the final month of life.
For the study, researchers sought to investigate factors associated with emergency department attendance by patients with cancer during the last month of their lives. They analyzed data from five electronic databases and identified 30 studies that investigated emergency department attendance at the end of the lives of patients with cancer.
The studies included nearly 1.2 million patients from five countries and reported 13 environmental, five clinical, and three demographic factors in total.
Results showed an increased risk of emergency department attendance was associated with black race (OR = 1.45; 95% CI: 1.40 - 1.50), male gender (OR = 1.24; 95% CI: 1.19 - 1.29), having lung cancer (OR = 1.17; 95% CI: 1.10 - 1.23), and those of low socioeconomic status (OR = 1.15; 95% CI: 1.10 - 1.19).
Patients receiving palliative care were less likely to have an emergency department visit during the last month of life (OR = 0.43; 95% CI: 0.36 - 0.51).
Demographic and environmental factors associated with an increased risk of emergency department visits by patients with cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|